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Glioblastoma (GB, grade IV astrocytoma) is highly proliferating, infiltrating, and 
relapsing. So far, no therapy cures the disease and on average lethality occurs with-
in 2 years from diagnosis. Despite the intimate molecular mechanisms of GB remain 
unknown, the mammalian Target Of Rapamycin (mTOR) is constantly upregulated 
within GB and in other astrocytomas. Consistently, mTOR was proposed as a target 
to cure GB. In fact, the mTOR inhibitor rapamycin was tested in order to prevent 
the growth of GB in human primary cultures and in mouse xenograft. Cytopathol-
ogy of GB is highly heterogeneous for the co-existence of various cell types and the 
occurrence progressive steps in cell differentiation. Remarkably, the non differentiat-
ed stem-like cells represent primary GB precursors which initiate the tumor growth. 
Altered transmission of pathological proteins was recently claimed to underly the 
growth of GB and its infiltration. These proteins are controlled by the mTOR pathway 
and spread from cell to cell suggesting a prion-like mechanism in GB. Therefore, in 
the present study, using the human GB cell line U87MG, we evaluated the effect of a 
wide range of rapamycin concentrations (between 1 nM to 1 x 103 nM) at 24 h on: cell 
survival; cell morphology and electrophysiology; cell differentiation and migration; 
expression of PrP and other prion-like proteins.
We found that effects of rapamycin on U87MG are dose-dependent. While high dos-
es (100 nM up to 1000 nM) reduce cell viability, lower rapamycin doses (1nm up to 10 
nM) produce cell differentiation consisting of morphological and immunohistochemical 
changes. Rapamycin promotes a neuronal shape with process elongation and increased 
cell size. This associates with the loss of the staminal marker nestin while the early neu-
ronal marker betaIII-tubulin increases. At 24 h rapamycin inhibits U87MG cell migra-
tion dose-dependently. The neuronal morphology associates with altered intracellular 
calcium flux but not neuronal electrophysiological properties. Finally, expression of pri-
onoids which we found to be high in baseline conditions was suppressed by rapamy-
cin. This is consistent with our ultrastructural findings which substantiate the dramatic 
effects induced by mTOR inhibition. Our results suggests pathological cell communica-
tion in GB while providing cellular evidence supporting the use of rapamycin as well 
rapalogs as effective drugs to treat malignant astrocytoma.
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